Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1747MR)

This product GTTS-WQ1747MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1747MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4936MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ10139MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ7082MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ3093MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ2574MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ2805MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ13490MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ7929MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK3196165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW